Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
RevOpsis Therapeutics logo — Harnessing a new era of multispecific biologics to discover...

RevOpsis Therapeutics

Harnessing a new era of multispecific biologics to discover ​ and develop breakthrough treatments

Founded 2022 5 employees Seed Total: $24.40M Health Care, Life Sciences

General Information

Company Name RevOpsis Therapeutics
Founded Year 2022
Employees 5
Industries Health Care, Life Sciences
Funding Stage Seed
Social

Get notified when RevOpsis Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About RevOpsis Therapeutics

RevOpsis Therapeutics is a next-generation biopharmaceutical company pioneering a new era in multispecific antibody discovery and development. Their proprietary Rev-Mod Platform utilizes a modular plug-and-play system with a library of ~30 billion fully human and fully compatible antibody components, simplifying drug discovery. Their lead asset, RO-104, is a first-in-class trispecific biologic targeting three clinically validated pathways implicated in retinal vascular diseases. The company recently secured a $9.00M Seed Round investment on 25 April 2024 to advance their groundbreaking research. RevOpsis Therapeutics presents an exciting opportunity for investors seeking to support innovative approaches to complex disease treatment within the Health Care and Life Sciences industries.

Taxonomy: biopharmaceutical, multispecific antibodies, drug discovery, therapeutic development, retinal vascular diseases, neovascular age-related macular degeneration, ophthalmology, trispecific biologic, VEGF, Ang-2, preclinical studies, vision loss, biotech startup, Rev-Mod Platform, Surrobody platform

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Grant •••••• - 25 Apr 2024
Seed Round •••••• - 25 Apr 2024
Venture Round •••••• - 09 Aug 2023

FAQ About RevOpsis Therapeutics

Harnessing a new era of multispecific biologics to discover ​ and develop breakthrough treatments
RevOpsis Therapeutics was founded in 2022.
RevOpsis Therapeutics operates in the following industries: Health Care, Life Sciences.
RevOpsis Therapeutics has approximately 5 employees.
RevOpsis Therapeutics has completed 3 funding rounds, raising a total of $24.40M. The latest funding stage is Seed.

We're actively collecting intelligence on RevOpsis Therapeutics.

Track RevOpsis Therapeutics to get notified

Don't just browse. Track.

Signal Tracker monitors RevOpsis Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy